|
Illert, Anna Lena; Kawaguchi, Hiroyuki; Antinozzi, Cristina et al. (2012) Targeted inactivation of nuclear interaction partner of ALK disrupts meiotic prophase. Development 139:2523-34
|
|
Weiss, Joseph B; Xue, Changhui; Benice, Ted et al. (2012) Anaplastic lymphoma kinase and leukocyte tyrosine kinase: functions and genetic interactions in learning, memory and adult neurogenesis. Pharmacol Biochem Behav 100:566-74
|
|
Webb, Thomas R; Slavish, Jake; George, Rani E et al. (2009) Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 9:331-56
|
|
Li, Rongshi; Pourpak, Alan; Morris, Stephan W (2009) Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 52:4981-5004
|
|
Jake Slavish, P; Jiang, Qin; Cui, Xiaoli et al. (2009) Design and synthesis of a novel tyrosine kinase inhibitor template. Bioorg Med Chem 17:3308-16
|
|
Kadin, Marshall E; Pinkus, Jack L; Pinkus, Geraldine S et al. (2008) Primary cutaneous ALCL with phosphorylated/activated cytoplasmic ALK and novel phenotype: EMA/MUC1+, cutaneous lymphocyte antigen negative. Am J Surg Pathol 32:1421-6
|
|
George, Rani E; Sanda, Takaomi; Hanna, Megan et al. (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-8
|
|
Li, Rongshi; Morris, Stephan W (2008) Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28:372-412
|
|
Bassermann, Florian; von Klitzing, Christine; Illert, Anna Lena et al. (2007) Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1. J Biol Chem 282:15965-72
|
|
Li, Rongshi; Xue, Liquan; Zhu, Tong et al. (2006) Design and synthesis of 5-aryl-pyridone-carboxamides as inhibitors of anaplastic lymphoma kinase. J Med Chem 49:1006-15
|
Showing the most recent 10 out of 50 publications
